Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Vladimir, Simov"'
Autor:
David A. Candito, Vladimir Simov, Anmol Gulati, Solomon Kattar, Ryan W. Chau, Blair T. Lapointe, Joey L. Methot, Duane E. DeMong, Thomas H. Graham, Ravi Kurukulasuriya, Mitchell H. Keylor, Ling Tong, Gregori J. Morriello, John J. Acton, Barbara Pio, Weiguo Liu, Jack D. Scott, Michael J. Ardolino, Theodore A. Martinot, Matthew L. Maddess, Xin Yan, Hakan Gunaydin, Rachel L. Palte, Spencer E. McMinn, Lisa Nogle, Hongshi Yu, Ellen C. Minnihan, Charles A. Lesburg, Ping Liu, Jing Su, Laxminarayan G. Hegde, Lily Y. Moy, Janice D. Woodhouse, Robert Faltus, Tina Xiong, Paul Ciaccio, Jennifer A. Piesvaux, Karin M. Otte, Matthew E. Kennedy, David Jonathan Bennett, Erin F. DiMauro, Matthew J. Fell, Santhosh Neelamkavil, Harold B. Wood, Peter H. Fuller, J. Michael Ellis
Publikováno v:
Journal of Medicinal Chemistry. 65:16801-16817
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::365ba0e1a6a6d085b4344b637344b726
https://doi.org/10.1021/acs.jmedchem.2c01605
https://doi.org/10.1021/acs.jmedchem.2c01605
Publikováno v:
Cells, Vol 10, Iss 10, p 2715 (2021)
The Hippo pathway is an evolutionary conserved signaling network that regulates essential processes such as organ size, cell proliferation, migration, stemness and apoptosis. Alterations in this pathway are commonly found in solid tumors and can lead
Externí odkaz:
https://doaj.org/article/6c91c4c22e394ec0b8aca08e37c938bd
Autor:
Chunhui Huang, Christian Fischer, Michelle R. Machacek, Stephane Bogen, Tesfaye Biftu, Xianhai Huang, Michael H. Reutershan, Ryan Otte, Qingmei Hong, Zhicai Wu, Yang Yu, Min Park, Lei Chen, Purakkattle Biju, Ian Knemeyer, Ping Lu, Christopher J. Kochansky, Michael Brendan Hicks, Yong Liu, Roy Helmy, Xavier Fradera, Anthony Donofrio, Josh Close, Matthew L. Maddess, Catherine White, David L. Sloman, Nunzio Sciammetta, Jun Lu, Craig Gibeau, Vladimir Simov, Hongjun Zhang, Peter Fuller, David Witter
Publikováno v:
ACS Med Chem Lett
[Image: see text] Mutant isocitrate dehydrogenase 1 (IDH1) has been identified as an attractive oncology target for which >70% of grade II and III gliomas and ∼10% of acute myeloid leukemia (AML) harbor somatic IDH1 mutations. These mutations confe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13ecfd534a4182e5c705a82b16c3ffcc
https://europepmc.org/articles/PMC9014435/
https://europepmc.org/articles/PMC9014435/
Autor:
Matthew H. Daniels, Sunil Nagpal, Blair T. Lapointe, Jos Cals, Mario van der Stelt, Vladimir Simov, Willem Jan Karstens, Sujal V. Deshmukh, Kenneth Jay Barr, J. Richard Miller, Hans van Eenenaam, Craig C. Correll, John Maclean, Laxminarayan G Hegde, Lily Y. Moy, B. Wesley Trotter, Rachel L. Palte, Janice D Woodhouse, Nunzio Sciammetta, Gopal Parthasarathy, Heidi Ferguson, Rita Azevedo, Hongjun Zhang, Arthur Oubrie, Neville J. Anthony
Publikováno v:
ACS Medicinal Chemistry Letters. 11:114-119
The clinical success of anti-IL-17 monoclonal antibodies (i.e., Cosentyx and Taltz) has validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear hormone receptor RORγt is a master regulator of Th17 cells and affects th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::927a9a20903f38d39770d2e5897d3e47
https://doi.org/10.1021/acsmedchemlett.9b00431
https://doi.org/10.1021/acsmedchemlett.9b00431
Autor:
Douglas C. Beshore, Andrew M. Haidle, Ashok Arasappan, Yeon-Hee Lim, Izzat Raheem, Anthony J. Roecker, Samantha E. Shockley, Vladimir Simov
Publikováno v:
Journal of medicinal chemistry. 65(5)
Increasing the efficiency of the drug discovery process is a challenge faced by drug hunters everywhere. One strategy medicinal chemists employ to meet this challenge is learning from knowledge sources within and beyond their organization. In this Pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad891faa2666135678b417ae5aa9b632
https://pubmed.ncbi.nlm.nih.gov/35192762
https://pubmed.ncbi.nlm.nih.gov/35192762
Autor:
Mitchell H. Keylor, Anmol Gulati, Solomon D. Kattar, Rebecca E. Johnson, Ryan W. Chau, Kaila A. Margrey, Michael J. Ardolino, Cayetana Zarate, Kelsey E. Poremba, Vladimir Simov, Gregori J. Morriello, John J. Acton, Barbara Pio, Xin Yan, Rachel L. Palte, Spencer E. McMinn, Lisa Nogle, Charles A. Lesburg, Donovon Adpressa, Shishi Lin, Santhosh Neelamkavil, Ping Liu, Jing Su, Laxminarayan G. Hegde, Janice D. Woodhouse, Robert Faltus, Tina Xiong, Paul J. Ciaccio, Jennifer Piesvaux, Karin M. Otte, Harold B. Wood, Matthew E. Kennedy, David Jonathan Bennett, Erin F. DiMauro, Matthew J. Fell, Peter H. Fuller
Publikováno v:
Journal of medicinal chemistry. 65(1)
The leucine-rich repeat kinase 2 (LRRK2) protein has been genetically and functionally linked to Parkinson's disease (PD), a disabling and progressive neurodegenerative disorder whose current therapies are limited in scope and efficacy. In this repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6720c280fccf3e18653a864a196348ad
https://pubmed.ncbi.nlm.nih.gov/34967623
https://pubmed.ncbi.nlm.nih.gov/34967623
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors
Autor:
Blair T. Lapointe, Jack D. Scott, Xin Cindy Yan, Haiqun Tang, Janice D Woodhouse, Kaleen Konrad Childers, Robert Faltus, Erin F. DiMauro, Solomon Kattar, Charles S. Yeung, Ravi Kurukulasuriya, Vladimir Simov, Hakan Gunaydin, Anmol Gulati, Joey L. Methot, Rachel L. Palte, Ellen C. Minnihan, Greg Morriello, J. Michael Ellis, Harold B. Wood, Santhosh Neelamkavil, Karin M. Otte, Michael J. Ardolino, Barbara Pio, Ping Liu, Laxminarayan G Hegde, Matthew J. Fell, Vanessa L. Rada, Peter Fuller, Paul J Ciaccio
Publikováno v:
RSC Med Chem
The discovery of potent, kinome selective, brain penetrant LRRK2 inhibitors is the focus of extensive research seeking new, disease-modifying treatments for Parkinson's disease (PD). Herein, we describe the discovery and evolution of a picolinamide-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c8d45ea7dd7adda70471298a4476afa
https://europepmc.org/articles/PMC8292993/
https://europepmc.org/articles/PMC8292993/
Autor:
Abbas Walji, Sonia DelRizzo, Elisabetta Bianchi, Jonathan D. Mortison, Vladimir Simov, Yingzi Yue, Thomas J. Tucker, Peter Goldenblatt, Alexander Stoeck, Raffaele Ingenito, Edward DiNunzio, Christopher Sondey, Hui Wan, Erin F. DiMauro, Venkat Sriraman, Victor Serebrov, My Sam Mansueto, Scott A. Johnson, Todd Mayhood, Guo Feng, Michael D. Altman
Publikováno v:
European journal of medicinal chemistry. 224
Pathway activating mutations of the transcription factor NRF2 and its negative regulator KEAP1 are strongly correlative with poor clinical outcome with pemetrexed/carbo(cis)platin/pembrolizumab (PCP) chemo-immunotherapy in lung cancer. Despite the st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31b0d49161744ae4b7f2ebe6b8374f07
https://pubmed.ncbi.nlm.nih.gov/34303079
https://pubmed.ncbi.nlm.nih.gov/34303079
Publikováno v:
Cells, Vol 10, Iss 2715, p 2715 (2021)
Cells
Cells
The Hippo pathway is an evolutionary conserved signaling network that regulates essential processes such as organ size, cell proliferation, migration, stemness and apoptosis. Alterations in this pathway are commonly found in solid tumors and can lead
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf915d7a2b02379ed9a9cc87bb9f6181
https://doi.org/10.3390/cells10102715
https://doi.org/10.3390/cells10102715
Autor:
Hongjun, Zhang, Blair T, Lapointe, Neville, Anthony, Rita, Azevedo, Jos, Cals, Craig C, Correll, Matthew, Daniels, Sujal, Deshmukh, Hans, van Eenenaam, Heidi, Ferguson, Laxminarayan G, Hegde, Willem Jan, Karstens, John, Maclean, J Richard, Miller, Lily Y, Moy, Vladimir, Simov, Sunil, Nagpal, Arthur, Oubrie, Rachel L, Palte, Gopal, Parthasarathy, Nunzio, Sciammetta, Mario, van der Stelt, Janice D, Woodhouse, B Wesley, Trotter, Kenneth, Barr
Publikováno v:
ACS Med Chem Lett
[Image: see text] The clinical success of anti-IL-17 monoclonal antibodies (i.e., Cosentyx and Taltz) has validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear hormone receptor RORγt is a master regulator of Th17 ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b04108fd54b05ba3642d5229b4061176
https://pubmed.ncbi.nlm.nih.gov/32071676
https://pubmed.ncbi.nlm.nih.gov/32071676